Rana McKay, MD
Hematology & Oncology · San Diego, CANPI 1306013610
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $363,369 of the $530,093 with a category attached, or 68.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 22.9%. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $1398.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$122K
- Bayer$65K
- Pfizer$56K
- Exelixis Inc.$51K
- Astrazeneca UK Limited$42K
- E.r. Squibb & Sons, L.L.C.$31K
- plus $164K from 24 others
Across 898 payments — averaging $16,449 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.6M
- Exelixis Inc.$3.3M
- AstraZeneca$3M
- Seagen Inc.$784K
- Bayer$731K
- Janssen Research & Development, LLC$585K
- plus $1.8M from 11 others
What the payments were for
- Consulting fees$363,36969%
- Speaking & faculty fees$131,91625%
- Travel & lodging$28,0535%
- Food & beverage$6,5611%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 53 | $121,625 |
| Bayer | 54 | $65,398 |
| Pfizer | 33 | $55,691 |
| Exelixis Inc. | 63 | $50,703 |
| Astrazeneca UK Limited | 17 | $41,895 |
| E.r. Squibb & Sons, L.L.C. | 36 | $31,173 |
| Novartis | 15 | $26,458 |
| Daiichi Sankyo Inc. | 12 | $18,230 |
| Sanofi | 7 | $17,555 |
| AstraZeneca | 20 | $15,072 |
| Dendreon Pharmaceuticals LLC | 11 | $12,554 |
| Astellas Pharma US Inc | 3 | $11,201 |
| AVEO Pharmaceuticals, Inc. | 9 | $10,561 |
| Seagen Inc. | 6 | $7,036 |
| Janssen Scientific Affairs, LLC | 6 | $6,458 |
| Eli Lilly | 2 | $5,400 |
| Johnson & Johnson(2 entities) | 4 | $5,186 |
| Telix Pharmaceuticals | 7 | $4,304 |
| Janssen Research & Development, LLC | 4 | $4,278 |
| Eisai Inc. | 5 | $4,243 |
| Ipsen Pharma SAS | 1 | $3,488 |
| Takeda Pharmaceutical Company, Limited | 1 | $3,043 |
| Gilead | 2 | $2,432 |
| Blue Earth Diagnostics | 2 | $2,016 |
| Advanced Accelerator Applications | 1 | $1,713 |
| Janssen Global Services, LLC | 1 | $1,650 |
| Sun Pharmaceutical Industries Inc. | 1 | $500 |
| Sumitomo Pharma America, Inc. | 1 | $106 |
| Intuitive Surgical | 1 | $97 |
| Caris MPI, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$530,093 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 11 | $314,995 |
| XtandiEnzalutamide | 18 | $237,465 |
| Abiraterone Acetate | 43 | $100,442 |
| OrgovyxRelugolix | 29 | $75,078 |
| EliquisApixaban | 12 | $6,886 |
| Prochlorperazine Maleate | 18 | $390 |
| Prednisone | 55 | $275 |
| Levothyroxine Sodium | 16 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $50,703 | $314,99511 claims |
| Astellas Pharma US IncXtandi | $11,201 | $237,46518 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $6,458 | $100,44243 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $106 | $75,07829 claims |
| PfizerEliquis | $55,691 | $6,88612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.